Statements (77)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Yervoy
|
| gptkbp:activities |
PD-1 inhibitor
inhibits PD-1 receptor |
| gptkbp:approves |
gptkb:healthcare_organization
gptkb:classical_Hodgkin_lymphoma gptkb:FDA esophageal cancer head and neck cancer urothelial carcinoma |
| gptkbp:average_temperature |
2 to 8 ° C
|
| gptkbp:capacity |
2 m L
|
| gptkbp:clinical_trial |
gptkb:KEYNOTE-001
gptkb:KEYNOTE-024 gptkb:KEYNOTE-189 gptkb:KEYNOTE-407 gptkb:KEYNOTE-598 Phase 1 combination therapy Phase 2 Phase 3 first-line therapy second-line therapy KEYNOTE-010 |
| gptkbp:competitors |
gptkb:Atezolizumab
gptkb:Cemiplimab gptkb:Durvalumab gptkb:Opdivo |
| gptkbp:effective_date |
September 2014
|
| gptkbp:frequency |
every 3 weeks
|
| gptkbp:healthcare |
gptkb:2014
|
| https://www.w3.org/2000/01/rdf-schema#label |
Keytruda
|
| gptkbp:indication |
gptkb:healthcare_organization
gptkb:malignant_pleural_mesothelioma gptkb:primary_mediastinal_large_B-cell_lymphoma gptkb:cervical_cancer gptkb:Wilms_tumor gptkb:neuroblastoma ovarian cancer liver cancer esophageal cancer small cell lung cancer neuroendocrine tumors germ cell tumors esophageal squamous cell carcinoma advanced melanoma MDS (myelodysplastic syndromes) advanced renal cell carcinoma CML (chronic myeloid leukemia) advanced urothelial carcinoma malignant peritoneal mesothelioma metastatic lung cancer recurrent head and neck squamous cell carcinoma relapsed classical Hodgkin lymphoma |
| gptkbp:ingredients |
gptkb:pembrolizumab
C153 H212 N302 O44 S |
| gptkbp:invention |
2028
|
| gptkbp:is_a |
cancer immunotherapy
|
| gptkbp:is_used_for |
treatment of melanoma
treatment of Hodgkin lymphoma treatment of bladder cancer treatment of lung cancer treatment of head and neck cancer |
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketed_as |
gptkb:pembrolizumab
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash immune-mediated reactions pruritus |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:PD-1
|
| gptkbp:website |
intravenous infusion
|
| gptkbp:weight |
149 k Da
|